---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-163498"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T03:55:04.040691+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma prices $107.5M public offering of 5M shares at $17.50, plus pre-funded warrants

## Summary
- Offering: 5,000,000 ordinary shares at $17.50/share plus 1,142,857 pre-funded warrants at $17.499 each.
- Gross proceeds expected to be approximately $107.5 million before underwriting discounts and expenses.
- Underwriters granted a 30-day option to purchase up to an additional 921,428 ordinary shares.
- Closing expected on June 20, 2024, subject to customary conditions.
- TD Cowen and Guggenheim Securities are joint book-running managers; Oppenheimer & Co. is lead manager.

## SEC filing metadata
- accession: 0001193125-24-163498
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524163498/0001193125-24-163498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524163498/d854991d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-163498
- JSON: https://secwatch.observer/filing/0001193125-24-163498.json
- Plain text: https://secwatch.observer/filing/0001193125-24-163498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.